18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis

  • Julie Obert
  • Laetitia Vercellino
  • Axel Van Der Gucht
  • Constance de Margerie-Mellon
  • Emmanuelle Bugnet
  • Sylvie Chevret
  • Gwenaël Lorillon
  • Abdellatif Tazi
Original Article



The standard evaluation of multisystem Langerhans cell histiocytosis (LCH) includes a clinical evaluation, laboratory tests and a skeleton/skull X-ray survey, with chest high-resolution computed tomography (HRCT) in the case of pulmonary involvement. Preliminary reports suggest that 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) may be useful for evaluating patients with LCH.


Fourteen consecutive adult patients with multisystem LCH were included in this retrospective study, and were evaluated using standard procedures and 18F-FDG PET-CT. The two sets of findings were compared both at baseline and during follow-up. Serial HRCT and pulmonary function tests were used to evaluate outcome in patients with lung involvement.


At the baseline evaluation, PET-CT identified every LCH localization found with the standard evaluation (except a mild cecum infiltration). PET-CT showed additional lesions in seven patients, mostly involving bones, and differentiated inactive from active lesions. Thyroid 18F-FDG uptake was identified in three cases. No pituitary stalk 18F-FDG uptake was observed in patients with pituitary LCH. Only 3/12 (25 %) patients with pulmonary LCH displayed moderate pulmonary 18F-FDG uptake. During follow-up, variations (≥50 % of maximum standardized uptake) in bone 18F-FDG uptake intensity were correlated with disease state and response to treatment. The absence of lung 18F-FDG uptake did not preclude lung function improvement after treatment.


Except for cases with pulmonary and pituitary involvement, 18F-FDG PET-CT could replace the standard evaluation for staging of adult patients with multisystem LCH. Serial PET-CT scans are useful for evaluating treatment responses, particularly in cases with bone LCH involvement.


Langerhans cell histiocytosis PET-CT Management Response to treatment 


  1. 1.
    Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Picarsic J, Jaffe R. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015;29:799–823.CrossRefPubMedGoogle Scholar
  3. 3.
    Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol. 2006;76:363–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Weitzman S, Egeler RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008;20:23–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Suri H, Yi ES, Nowakowski GS, Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis. 2012;7:16.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, et al. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015;10:30.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet. 1987;1:208–9.Google Scholar
  8. 8.
    Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Meyer JS, Harty MP, Mahboubi S, Heyman S, Zimmerman RA, Womer RB, et al. Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics. 1995;15:1135–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Kaste SC, Rodriguez-Galindo C, McCarville ME, Shulkin BL. PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol. 2007;37:615–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52:97–101.CrossRefPubMedGoogle Scholar
  12. 12.
    Binkovitz LA, Olshefski RS, Adler BH. Coincidence FDG-PET in the evaluation of Langerhans’ cell histiocytosis: preliminary findings. Pediatr Radiol. 2003;33:598–602.CrossRefPubMedGoogle Scholar
  13. 13.
    Blum R, Seymour JF, Hicks RJ. Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma. 2002;43:2155–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Lee HJ, Ahn BC, Lee SW, Lee J. The usefulness of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Langerhans cell histiocytosis. Ann Nucl Med. 2012;26:730–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Krajicek BJ, Ryu JH, Hartman TE, Lowe VJ, Vassallo R. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest. 2009;135:1542–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Canuet M, Kessler R, Jeung MY, Metivier AC, Chaouat A, Weitzenblum E. Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis. Respiration. 2007;74:640–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Tazi A, Marc K, Dominique S, de Bazelaire C, Crestani B, Chinet T, et al. Serial computed tomography and lung function testing in pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2012;40:905–12.CrossRefPubMedGoogle Scholar
  18. 18.
    European Respiratory Society. Standardized lung function testing. Eur Respir J Suppl. 1993;16:1–100.Google Scholar
  19. 19.
    Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:327–38.CrossRefPubMedGoogle Scholar
  21. 21.
    Goo HW, Yang DH, Ra YS, Song JS, Im HJ, Seo JJ, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006;36:1019–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Mueller WP, Melzer HI, Schmid I, Coppenrath E, Bartenstein P, Pfluger T. The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging. 2013;40:356–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Adam Z, Szturz P, Vanicek J, Moulis M, Pour L, Krejci M, et al. Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: a single-center study of seven cases. Acta Oncol. 2013;52:994–1001.CrossRefPubMedGoogle Scholar
  24. 24.
    Cai YF, Wang QX, Ni CJ, Dong SY, Lv L, Li Q, et al. A case report: the diagnosis and therapeutic evaluation for a rare disease of langerhans cell histiocytosis involving thyroid. Medicine (Baltimore). 2015;94:e1891.CrossRefGoogle Scholar
  25. 25.
    Giovanella L, Ceriani L, Crippa S, Mazzucchelli L. Imaging in endocrinology: Langherans cell histiocytosis of the thyroid gland detected by 18FDG-PET/CT. J Clin Endocrinol Metab. 2007;92:2866–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Uchiyama M, Watanabe R, Ito I, Ikeda T. Thyroid involvement in pulmonary Langerhans cell histiocytosis. Intern Med. 2009;48:2047–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Vergez S, Rouquette I, Ancey M, Serrano E, Caron P. Langerhans cell histiocytosis of the thyroid is a rare entity, but an association with a papillary thyroid carcinoma is often described. Endocr Pathol. 2010;21:274–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Das DK, Sheikh ZA, Alansary TA, Amir T, Al-Rabiy FN, Junaid TA. A case of Langerhans’ cell histiocytosis associated with Hodgkin’s lymphoma: fine-needle aspiration cytologic and histopathological features. Diagn Cytopathol. 2016;44:128–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Naumann R, Beuthien-Baumann B, Fischer R, Kittner T, Bredow J, Kropp J, et al. Simultaneous occurrence of Hodgkin’s lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. Clin Lymphoma. 2002;3:121–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Julie Obert
    • 1
    • 2
  • Laetitia Vercellino
    • 3
  • Axel Van Der Gucht
    • 1
    • 3
  • Constance de Margerie-Mellon
    • 1
    • 4
  • Emmanuelle Bugnet
    • 2
  • Sylvie Chevret
    • 1
    • 5
    • 6
  • Gwenaël Lorillon
    • 2
  • Abdellatif Tazi
    • 1
    • 2
    • 6
  1. 1.Université Paris DiderotParisFrance
  2. 2.Centre National de Référence de l’Histiocytose Langerhansienne, Service de Pneumologie, Hôpital Saint-LouisAssistance Publique-Hôpitaux de ParisParisFrance
  3. 3.Service de Médecine Nucléaire, Hôpital Saint-LouisAssistance Publique-Hôpitaux de ParisParisFrance
  4. 4.Service de Radiologie, Hôpital Saint-LouisAssistance Publique-Hôpitaux de ParisParisFrance
  5. 5.Service de Biostatistique et Information Médicale, Hôpital Saint-LouisAssistance Publique-Hôpitaux de ParisParisFrance
  6. 6.U1153 CRESSBiostatistics and Clinical Epidemiology Research TeamParisFrance

Personalised recommendations